Acute Porphyria Drug Database

L01FE02 - Panitumumab
Not porphyrinogenic
NP

Rationale
No CYP-affinity. No conceivable effects on PXR activation. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Panitumumab is a recombinant human IgG2 kappa monoclonal antibody that specifically binds to the human epidermal growth factor receptor (EGFR, HER1, c-erbB-1).
Therapeutic characteristics
Panitumumab is an antineoplastic agent used in the treatment of colorectal cancer metastases with wild type KRAS after chemotherapeutic failure. It is administered as an intravenous infusion. Common adverse reactions of panitumumab that can be confused with an acute porphyric attack are diarrhoea, nausea, vomiting, and dyspnoea. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Metabolism and pharmacokinetics
Panitumumab is metabolized in the same way as endogenous IgG. Non-CYP metabolism.

References

  1. Drug reference publications
  2. McEvoy GK, editor. Panitumumab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (25.05.10). #2050
  3. Sweetman SC, editor. Martindale: The complete drug reference. Panitumumab. Pharmaceutical Press 2009. #2052
  4. Summary of Product Characteristics
  5. Norwegian medicines agency. Summary of Product Characteristics (SPC). Vectibix. #2051

Similar drugs
Explore alternative drugs in similar therapeutic classes L01F / L01FE or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙